Background: To prospectively assess the efficacy of bilateral risk-reducing mastectomy (BRRM) when compared with surveillance on breast cancer (BC) risk and mortality in healthy BRCA1 and BRCA2 mutation carriers.
introduction
Women with a germline BRCA1 or BRCA2 mutation are at increased risk of developing breast and/or ovarian cancer compared with the general population [1] [2] [3] [4] . Options to reduce breast cancer (BC) risk and/or subsequent mortality are regular surveillance with magnetic resonance imaging (MRI) and mammography, chemoprevention, and bilateral riskreducing mastectomy (BRRM). Further, risk-reducing salpingo-oophorectomy (RRSO) aiming at reduction of ovarian cancer risk also reduces the risk of BC [5] .
Knowledge on the efficacy of the different risk-reducing strategies is important to both counsellors and BRCA1/2 mutation carriers, the latter facing the difficult decision of having their healthy breasts removed in order to prevent BC and possibly achieve better survival.
Previous publications, including the study by MeijersHeijboer et al. from our institute, reported reduction of BC risk after BRRM in healthy BRCA1 or BRCA2 mutation carriers [6] [7] [8] [9] [10] . However, most studies were limited by small sample sizes, short follow-up periods, and retrospective study designs, thus facing methodological limitations, especially biases associated with start of follow-up such as cancer-induced testing bias and familial event bias [11] . Clearly, for ethical reasons randomized studies on risk-reducing strategies in BRCA1/2 mutation carriers are not feasible. Still, observational studies in BRCA1/2 mutation carriers can be set up in a prospective design, providing similar baseline risk for all study subjects, by starting the follow-up at the date of individual DNA diagnosis and excluding subjects having the event of interest before that date [11] .
Further, to date, no prospective data are available regarding survival in healthy BRCA1 and BRCA2 mutation carriers comparing BRRM with regular surveillance. The only available information hereon is derived from risk estimates assessed in mathematical models with simulated cohorts, yielding maximal survival probability for BRCA1/2 mutation carriers undergoing both BRRM and RRSO [12] [13] [14] [15] [16] , although Kurian et al. suggested that surveillance using mammography and MRI in combination with RRSO might offer almost comparable survival [14, 16] . In view of surveillance aiming at early BC detection, and the current availability of modern (neo)adjuvant treatment strategies, it can indeed be hypothesized that regular surveillance may lead to similar survival when compared with BRRM.
The purpose of the current prospective study was to compare the rates of BC incidence, all cause mortality and BCspecific mortality in healthy BRCA1 and BRCA2 mutation carriers opting for either BRRM or regular surveillance.
methods study population
For this prospective cohort study, women were selected from the institutional Family Cancer Clinic registry database considering the following eligibility criteria: (i) proven BRCA1 or BRCA2 mutation carrier, (ii) no history of cancer at the time of DNA testing, (iii) both breasts and both ovaries in situ at the time of DNA testing, and (iv) follow-up at the Family Cancer Clinic. Women with symptomatic BC before the first screening round were excluded. Written informed consent for prospective data collection was obtained from all included mutation carriers according to research protocols approved by the Medical Ethical Committee. A total of 570 women fulfilled the inclusion criteria. Eventually, 212 of these women chose to undergo BRRM before the end of the follow-up period (31 December, 2011), whereas the other 358 women remained under BC surveillance. Study follow-up started at the date of DNA diagnosis, being available as of 1994.
data collection
Data on the following variables were retrieved from the medical files: mutation status, dates of birth, individual DNA diagnosis, breast and/or ovarian cancer diagnosis, dates of and findings at BRRM and/or RRSO, disease recurrence, and death.
breast cancer surveillance and bilateral risk-reducing mastectomy Regular BC surveillance for BRCA1/2 mutation carriers consisted of (bi) annual clinical breast examination and annual mammography, while monthly breast self-examination was advised. As of 1998, annual MRI was added to the mammography, carried out within a 6 weeks time span. From 2007, imaging was carried out biannually, alternating mammography and MRI. Ultrasound and cytological/histological examinations were carried out on indication.
Women considering BRRM were discussed before surgery in the multidisciplinary hereditary tumour board. Since 2000, clinical breast examination and MRI within 3 months before BRRM were recommended. In case of malignant findings detected during this screening round, events were allocated to the surveillance group.
Ninety-seven percent of the skin-sparing BRRM procedures were carried out at our clinic. Mastectomy specimens were examined thoroughly according to protocol by the pathologist.
After BRRM, patients were seen yearly at the Family Cancer Clinic including physical examination in order to investigate the long-term medical effects of prophylactic surgery and breast reconstruction. No standard imaging examination was scheduled.
statistical analysis
For evaluation of person characteristics, the BRRM group included all women having undergone BRRM, and the surveillance group all women who did not. To estimate the efficacy of BRRM on the incidence of BC, the BC incidence rate for the group of women undergoing BRRM was compared with that of the surveillance group. To estimate the effect of BRRM on all cause mortality and BC-specific mortality, hazard ratios (HR) with the surveillance group as the reference group, and accompanying 95% confidence intervals (CI) were provided using Cox models, with BRRM as time-dependent covariate. Mutation status (i.e. BRCA1 or BRCA2 carrier), year of birth, age at DNA diagnosis and RRSO (as a time-dependent covariate) were considered as potential confounders.
For all women, start of follow-up was defined as the date of the individual DNA diagnosis. Women who underwent BRRM contributed person-years of observation (PYO) before surgery to the surveillance group, while PYO after surgery were contributed to the BRRM group. Of note, women with unexpected malignant findings in the mastectomy specimens contributed PYO to the surveillance group, from the date of DNA diagnosis until surgery, and the BC cases were counted as events in the surveillance group (no PYO contributed to the BRRM group). For the women not opting for BRRM, all PYO were contributed to the surveillance group.
The duration of PYO in the surveillance group ended on the date of the event of interest, being either the date of BC diagnosis for the BC incidence analysis or the date of death for the analyses on mortality rates, the date of BRRM, or the date of a censoring event, whichever came first. The duration of PYO in the BRRM group ended on similar end points as described for the surveillance group. Censoring events were date of last contact, study closing date (i.e. December 31, 2011), and for BC incidence analysis also death.
All P-values were two sided, and a significance level α = 00.05 was used. Analyses were carried out with STATA (version 12.0; StataCorp, College Station, TX).
results

study population
Of the 570 unaffected BRCA1/2 mutation carriers, eventually 156 BRCA1 and 56 BRCA2 mutation carriers opted for BRRM (Table 1) , at a median age of 34 and 37 years, respectively. The median follow-up was 8.5 years (range 0.6-17.8 years) for the women undergoing BRRM with 6.3 years after surgery (range 0.1-17.4 years), and 4.1 years (range 0.1-16.1 years) for the women under surveillance (data not shown). Compared with the surveillance group, the BRRM women underwent DNA testing in earlier years (2001 versus 2006) , and at younger age (33 versus 36 years); also they more often opted for RRSO (54% versus 38%), again at younger age (40 versus 47 years; Table 1 ).
breast cancer
After BRRM, no incident BC cases were observed during 1379 PYO, while during 2037 PYO 57 women in the surveillance group were diagnosed with BC. The corresponding incidence rates per 1000 PYO were 0 and 28, respectively (Table 2) . Tenyear BC-free survival was 100% for the BRRM and 74% for the surveillance group ( Figure 1A) .
The majority of the 57 breast tumours in the surveillance group (including unexpected malignant findings detected at original articles Annals of Oncology BRRM) were diagnosed at a favourable stage, including six cases of ductal carcinoma in situ (DCIS, 10%) and 37 T1N0 cases (66%; Table 3 ).
BC was detected more often in BRCA1 than in BRCA2 mutation carriers (20% versus 7%; P < 0.01), but the median age at BC diagnosis was not different (43 versus 44 years; data not shown). In BRCA2 mutation carriers, all breast tumours were detected at a favourable stage (DCIS or T1N0), while this was 72% in BRCA1 mutation carriers (Table 3) . All tumours (n = 57) original articles
Annals of Oncology
Unexpected malignant findings in the mastectomy specimens were found in six women (Table 4) . Two cases of DCIS concerned BRCA2 mutation carriers above 40 years. The invasive cases all concerned BRCA1 mutation carriers being ≤36 years, and in two women even being bilateral. Subsequent staging showed micrometastasis in only one patient. So far, all these women are still alive without recurrent disease.
metastatic breast cancer
Four of the 51 women diagnosed with invasive BC in the surveillance group developed metastatic BC 1.7-3.6 years after BC diagnosis (Table 5) , all being BRCA1 mutation carriers including three (75%) having triple-negative BC. The woman with hormone sensitive BC never received systemic therapy, neither at diagnosis (not indicated according to guidelines) nor for metastatic disease due to comorbidity (renal insufficiency). Of note, all four women died within 1 year after detection of metastatic disease.
In the BRRM group, one BRCA1 mutation carrier presented in 2001 with metastases in axillary lymph nodes, bone and liver, 3.5 years after BRRM. Histological examination of an axillary lymph node showed adenocarcinoma, being ER/PRpositive and Her2Neu-negative, consistent with BC. Neither preoperative workup in 1998, consisting of clinical breast examination and mammography carried out 3 months before BRRM (no MRI), nor re-examination of pathology slides and other remnant frozen tissue material showed a primary BC. This patient died of BC in 2006.
all cause and breast cancer-specific mortality All cause mortality rates ( per 1000 PYO) were 0.7 for the BRRM group and 2.7 for the surveillance group (Table 2) , yielding a HR of 0.20 (95% CI 0.02-1.68). Ten-year overall survival was 99% for the BRRM and 96% for the surveillance group ( Figure 1B) . In the surveillance group, two women with previous RRSO died of extra-ovarian peritoneal cancer 
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(diagnosed at age 50 and 61, respectively, no history of BC). The BC-specific mortality rates ( per 1000 PYO) were 1.8 for the surveillance group and 0.7 for the BRRM group, resulting in a HR of 0.29 (95% CI 0.03-2.61) ( Table 2) . Of note, adding potential confounding variables to the model did not change the HR with more than 10%.
discussion
This prospective cohort study in healthy BRCA1/2 mutation carriers showed that after BRRM the BC incidence rate was substantially reduced, compared with regular surveillance. Further, all cause mortality and BC-specific mortality rates were reduced, although significant survival benefits could not be claimed yet. Moreover, regular surveillance detected BC at mainly favourable stages.
To the best of our knowledge, this is the largest single institution, prospective cohort study on the efficacy of BRRM versus regular surveillance in healthy BRCA1/2 mutation carriers so far. Our data are in line with the results of other published retrospective studies [6] [7] [8] [9] [10] and illustrate that BRRM substantially reduces the BC risk. We did not observe any BC after BRRM in 212 mutation carriers after a median follow-up of 6.3 years, while in the studies of Rebbeck et al. [8] and Skytte et al. [10] , two and three BC cases were observed after BRRM in 102 and 96 women, respectively.
With the exception of the recent study by Skytte et al. [10] , the prospective character of most previous studies is debatable. Especially, strong cancer-induced testing bias is introduced by including patients undergoing genetic testing after BC diagnosis into the surveillance group. Clearly, for ethical reasons, it is not possible to perform a randomized clinical trial in this setting. Still, by limiting our study cohort to those women being cancer-free and having both breasts and ovaries in situ at the moment of DNA testing, and by starting to count PYO from the date of individual DNA diagnosis for all women, in our opinion we have approached the most unbiased possible prospective model to study the efficacy of BRRM on BC risk reduction in healthy BRCA1/2 mutation carriers.
However, the ultimate goal of risk-reducing mastectomy is to improve survival, eventually being the reason for a healthy woman to decide for this drastic intervention. So far, survival after BRRM is only studied in mathematical simulation models describing an improved survival for women who opt for riskreducing surgery [12] [13] [14] [15] [16] , although Kurian et al. [14, 16] estimated that screening by means of mammography and MRI plus RRSO results in almost similar survival when compared with BRRM combined with RRSO, suggesting that intensive MRI-based surveillance might be a reasonable alternative to BRRM. Arguments to support the latter are (1) MRI detects BC at an early stage in BRCA1/2 mutation carriers [17] [18] [19] [20] , (2) in a prospective MRI-detected series of BRCA1/2-associated patients the 5-year cumulative overall survival was 93% (95% CI 79% to 98%) [21] , (3) broad implementation of (neo) adjuvant systemic therapy in recent years results in improved BC survival [22] .
The (non-significant) mortality rate reduction after BRRM found in our study corresponds with an absolute survival benefit of 3% according to the Kaplan-Meier estimates, which is comparable to the 3%-5% decrement in survival described by Kurian et al. when MRI-based screening was carried out instead of BRRM [14, 16] . Our prospective data adds to the modelling study of Kurian, since they better reflect real practice, with only 38% of the women undergoing RRSO in the surveillance group of our study (versus 100% in Kurian's model), during surveillance BC mostly detected at a favourable stage (DCIS/T1N0, while Kurian incorporated BC characteristics at symptomatic detection in the model), and 59% of the BCs in the surveillance group of our study being triple-negative (data not incorporated in Kurian's model).
Our data concerning early detection are in concordance with the mentioned literature [17] [18] [19] [20] . In the surveillance group 76% of the BCs were detected at favourable stages (DCIS or T1N0). Nevertheless, four patients (all BRCA1 carriers) developed metastatic disease and died of BC, despite early detection or applied adjuvant chemotherapy. Notably, these BCs were all diagnosed before 2007, when mammography and MRI were carried out simultaneously once a year. From 2007 on, mammography and MRI were carried out alternating every 6 months, while MRI techniques also have been improved. In this series, no significant differences in grade, behaviour, size, and nodal status were observed between invasive BCs diagnosed before 2007 (n = 22) and from 2007 and beyond (n = 29), though the latter BCs tended to be somewhat smaller (T1a/b, 62% versus 36%; P = 0.175) and more often nodenegative (N0, 90% versus 77%; P = 0.228). However, since the mean follow-up after BC diagnosis in the latter group was only 1.7 years (versus 6.6 years for patients with BC diagnosis before 2007), no conclusions regarding a more favourable outcome can be drawn yet.
Noteworthy, the incidence of breast tumours was lower in BRCA2 than in BRCA1 mutation carriers, all BRCA2-associated tumours were detected at favourable stages, and so far, all these BRCA2 patients remained without recurrent disease. These findings may suggest that for BRCA2 mutation carriers, in contrast to BRCA1 mutation carriers, intensive surveillance indeed may lead to similar survival when compared with BRRM.
In our series, one woman experienced metastatic BC 3.5 years after BRRM. As neither before nor at BRRM, a primary tumour was diagnosed, we did not count this as a primary BC event. Reanalyzing the data by doing so resulted in BC incidence rates (per 1000 PYO) of 1 versus 28 for the BRRM and surveillance groups, respectively (HR 0.03; 95% CI 0.01-0.22).
Despite preoperative (imaging) examination, unexpected malignant findings were found in the mastectomy specimens of six women (2.8%), emphasizing the need for careful examination of the mastectomy specimens. Reassuringly, none of the women with unexpected malignant findings in our study sample has been diagnosed with recurrent disease, after a mean follow-up of 4.8 years since BC diagnosis.
In our study design, the PYO of the women with unexpected malignant findings at BRRM were allocated to the surveillance group, and also the tumours were counted as events in this group. Although these women initially opted for BRRM, and therefore, according to the intention-to-treat principle, assignment to the BRRM group can be argued, in our opinion, this is the most appropriate way to handle these unexpected original articles Annals of Oncology findings, since these events could not be prevented by BRRM anymore. Then again, this may have led to some overestimation of the BC risk in the surveillance group. Reanalyzing the data by excluding the women with unexpected malignant findings at BRRM rendered similar results for BC incidence rates and mortality rates (data not shown), thus not altering the conclusions of our analyses.
Despite the strengths of our study, including a prospective design with a large sample size from a single institution, a sufficiently long follow-up period for BC risk estimates, and regular control visits after BRRM, longer follow-up, and larger sample size are still warranted to truly establish that BRRM indeed results in improved survival when compared with intensive surveillance in BRCA mutation carriers. Moreover, larger numbers of especially BRCA2 mutation carriers are needed to specifically investigate whether a more conservative approach concerning risk-reducing mastectomy in BRCA2 versus BRCA1 mutation carriers may be justified.
In summary, we confirmed that BRRM substantially reduces BC occurrence in healthy BRCA1/2 mutation carriers. Further, this is the first prospective observational study suggesting that BRRM when compared with surveillance is associated with improved survival, although longer follow-up in combination with larger sample size are needed to confirm statistical significance. Our data are certainly worthwhile for the clinic as it provides more accurate information on life expectancy for healthy BRCA1/2 mutation carriers facing the difficult choice between BC surveillance and BRRM. 
